Posted on 12/20/16
Johnson & Johnson's Stock Price Defies Gravity But The Fundamentals Should Ground It Eventually
Johnson & Johnson (NYSE:JNJ) has had a fairly impressive 2016. JNJ began the year like all other stocks by following the market lower. But since its . . .
Posted on 12/20/16
Buy Johnson & Johnson In 2017
Johnson & Johnson (NYSE:JNJ) is one of the world's leading companies operating in the health care field. Throughout its history, the company has been consistently growing, . . .
Posted on 12/20/16
Better Buy: Celgene Corporation vs. Johnson & Johnson
Celgene (NASDAQ:CELG) stepped onto Johnson & Johnson's (NYSE:JNJ) turf in 2014 with its launch of Otezla. The drug competes head-to-head with J&J's Stelara in the psoriasis . . .
Posted on 12/20/16
Kindred Healthcare and Atlantic Health System Announce Plans for Inpatient Rehabilitation Hospital
LOUISVILLE, Ky. & MORRISTOWN, N.J.--(BUSINESS WIRE)--Kindred Healthcare, Inc. (NYSE:KND) and Atlantic Health System today announced the signing of a definitive agreement to create a joint venture to . . .
Posted on 12/19/16
The 12 Greatest Medical Breakthroughs of 2016
IMAGE SOURCE: GETTY IMAGES.With less than two weeks to go before we turn the page on 2016, we can look back on another largely successful year . . .
Posted on 12/19/16
The Most Expensive Drugs of 2016
Prescription drug prices have gotten out of control for many Americans and many insurers. Some drugs cost as much as premium sports cars. Here are the . . .
Posted on 12/19/16
3 Low-Volatility Biotech Stocks to Buy
Are you hesitant to buy biotech stocks because of their volatility? If so, it's understandable. Many biotech stocks are very volatile, with frequent big swings up . . .
Posted on 12/19/16
Johnson & Johnson Wisely Bids Adieu to Actelion
IMAGE SOURCE: GETTY IMAGES.The courtship is officially over. As reported by the Associated Press on Tuesday, Dec. 13, Johnson & Johnson (NYSE:JNJ) is no longer actively . . .
Posted on 12/19/16
Soligenix Closes Public Offering
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced . . .
Posted on 12/16/16
Recro Pharma Closes $40 Million Public Offering
MALVERN, Pa., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue-generating, specialty pharmaceutical company primarily focused on developing innovative products for hospitals and ambulatory . . .
Posted on 12/16/16
Medgenics Announces Name Change to Aevi Genomic Medicine
Medgenics, Inc. (NASDAQ: MDGN) today announced that the company has changed its name to Aevi Genomic Medicine, Inc. Aevi Genomic Medicine (pronounced "AHH-vee") is a name . . .
Posted on 12/16/16
Almac Connects to Exostar's Identity and Access Management Platform
eClinical Application Users Benefit from Single Sign-On Expediency & Enhanced Security Almac Clinical Technologies, part of the Almac Group, the world’s largest privately-held contract pharmaceutical development . . .
Posted on 12/15/16
Recro Pharma Prices $39 Million New Offering
Quick TakeRecro Pharma (NASDAQ:REPH) has priced its offering to sell approximately $39 million of new common stock.The company is developing promising pain treatments and is nearing . . .
Posted on 12/15/16
Better Buy: Pfizer Inc. vs. Merck
This year is turning out quite differently for two of the biggest pharmaceutical companies. Pfizer's (NYSE:PFE) stock is barely above where it started at the beginning . . .
Posted on 12/14/16
Pfizer (PFE) Management Presents at Guggenheim 4th Annual Boston Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE)Guggenheim 4th Annual Boston Healthcare ConferenceDecember 13, 2016 12:00 P.M. ETExecutivesIan C. Read - Chairman and CEOAnalystsUnidentified Analyst - GuggenheimUnidentified AnalystGreetings everyone, I hope . . .
Posted on 12/14/16
Pfizer Just Channeled Its Inner Martin Shkreli (and Paid for It)
IMAGE SOURCE: GETTY IMAGES.This is a point that probably doesn't need to be stated, but prescription drug prices are generally expensive -- and they're seemingly growing . . .
Posted on 12/14/16
3 Top Biotech Stocks to Buy on Sale
Despite the turmoil caused by the U.S. presidential election this year, biotech stocks still sport some of the richest valuations in the market. Even so, there . . .
Posted on 12/13/16
Recro Pharma Prices Stock Offering
MALVERN, Pa., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue-generating, specialty pharmaceutical company primarily focused on developing innovative products for hospitals and ambulatory . . .
Posted on 12/13/16
Soligenix Prices $5,277,000 Public Offering and Completes Listing on Nasdaq
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced . . .
Posted on 12/13/16
Better Buy: Johnson & Johnson vs. Procter & Gamble Co
IMAGE CREDIT: GETTY IMAGES.When people choose what stocks to help them fund decades of retirement, Procter & Gamble (NYSE:PG) and Johnson & Johnson (NYSE:JNJ) are two . . .
Posted on 12/13/16
3 Big Risks for Johnson & Johnson in 2017
Johnson & Johnson (NYSE:JNJ) shareholders can't complain too much about the stock's performance in 2016. However, there's certainly room for improvement when a member of the . . .
Posted on 12/13/16
Here's Why Trump's Pledge to Lower Drug Prices Is All Bark and No Bite
IMAGE SOURCE: DISNEY-ABC TELEVISION GROUP VIA FLICKR.In less than six weeks, President-elect Donald Trump will be inaugurated and become the 45th president of the United States. . . .
Posted on 12/12/16
Johnson & Johnson Is One Of The Few Deals Out There Worth Making
As of close of trading Friday, stocks closed at all time highs posting a strong week of gains. As the market screams higher, stocks trading at . . .
Posted on 12/12/16
Celldex Therapeutics, Inc.'s Biggest Win in 2016
Celldex Therapeutics (NASDAQ:CLDX) saw its stock take a huge nosedive in 2016. That's what happens when your lead product flops in a late-stage clinical study. Did . . .
Posted on 12/12/16
Can Trump Solve Pfizer's $80 Billion Problem?
Among publicly traded U.S.-based companies, pharma giant Pfizer (NYSE:PFE) has outshined nearly all of its peers in terms of stockpiling cash overseas. Specifically, the drugmaker divulged . . .
Philadelphia
